Survodutide FDA Approval Status 2026: Not Approved

Research-use supply note: Regulatory tracking is separate from lab supply. Survodutide remains investigational and is not supplied by Remy Research. This approval tracker is evidence and regulatory context, not a pharmacy or treatment guide. For separate UAE in-vitro laboratory supply context, see Retatrutide UAE, published batch reports, and wholesale pricing for qualified lab or distributor inquiries.

What is Survodutide FDA Approval Status in 2026?

Survodutide FDA approval status in 2026 is not approved. As of October 12, 2026, Boehringer Ingelheim still describes survodutide as investigational, SYNCHRONIZE-1 and SYNCHRONIZE-2 have reported Phase 3 data, and no NDA or MAA filing timeline has been announced. The MASH programme (LIVERAGE / LIVERAGE-Cirrhosis) continues to recruit and has not produced a Phase 3 readout in 2026 to date.

Boehringer Ingelheim has not publicly disclosed a filing date. Filing timing depends on the rest of the SYNCHRONIZE programme and the broader Phase 3 dataset, and any FDA review would then run on the agency’s standard cycle from submission. The FDA has granted Breakthrough Therapy Designation and Fast Track Designation tied to the MASH programme.

What is Survodutide?

Survodutide (BI 456906) is Boehringer Ingelheim’s once-weekly injectable dual agonist targeting both the GLP-1 receptor and the glucagon receptor. This dual mechanism is the core differentiator. While GLP-1 receptor activation reduces appetite and slows gastric emptying — the same pathway used by semaglutide and tirzepatide — glucagon receptor activation adds two distinct pharmacological effects: increased energy expenditure and improved hepatic lipid metabolism.

The glucagon component is what separates survodutide from the current generation of approved obesity drugs. Glucagon receptor activation may help preserve lean muscle mass during weight loss, a significant concern with GLP-1-only therapies where a portion of weight lost comes from lean tissue rather than fat. The dual mechanism also positions survodutide for metabolic dysfunction-associated steatohepatitis (MASH), where the glucagon pathway directly addresses liver fat accumulation. For a detailed mechanistic overview, see our survodutide dual agonist compound profile.

What the Phase 3 SYNCHRONIZE-1 Data Show

SYNCHRONIZE-1 reported in 2026 as the first Phase 3 obesity readout for survodutide. In adults with obesity or overweight, survodutide produced up to 16.6% body-weight reduction at 76 weeks (efficacy estimand), with absolute reduction up to 17.8 kg (~39.2 lb), versus 3.2% on placebo. The 16.6% figure is Boehringer’s “up to” result under the efficacy estimand, not a mean across doses. The peer-reviewed paper (le Roux et al., New England Journal of Medicine, 2026;395:776–787) reports the primary treatment-regimen results at week 76: −12.2% with 3.6 mg and −13.0% with 6.0 mg versus −5.4% on placebo (n=725). Gastrointestinal adverse events occurred in 80.9% and 89.7% versus 47.9%.

Phase 2 remains useful context. The earlier dose-ranging trial reported weight reduction up to ~19% at 46 weeks at the top dose, with a clear dose-response across 0.6 mg, 2.4 mg, 3.6 mg, and 4.8 mg arms. Phase 2b MASH data showed substantial liver-fat reduction driven by the glucagon-receptor arm, with MASH resolution achieved in roughly 64% of patients at the highest doses. These earlier liver-side signals are the rationale for the ongoing Phase 3 LIVERAGE / LIVERAGE-Cirrhosis programme, which has not produced a 2026 readout to date.

On absolute weight loss, SYNCHRONIZE-1 sits below the Phase 3 numbers for tirzepatide’s SURMOUNT-1 (~22.5% at 72 wk) and retatrutide’s TRIUMPH-1 (28.3% at 80 wk, efficacy estimand). Analyst commentary at the time of readout noted survodutide falls short of those two on the weight-loss axis but leaves the glucagon arm open as a differentiator on cardiometabolic and liver outcomes — arms that the remaining SYNCHRONIZE trials and LIVERAGE / LIVERAGE-Cirrhosis will need to settle. For broader pipeline context, see the 2026 obesity drug pipeline timeline.

What is the SYNCHRONIZE Phase 3 Program?

SYNCHRONIZE is Boehringer Ingelheim’s Phase 3 clinical programme evaluating survodutide in adults with obesity or overweight. The MASH path runs separately under LIVERAGE (F2–F3 fibrosis) and LIVERAGE-Cirrhosis (compensated cirrhosis), which continue to recruit.

SYNCHRONIZE-1 is a 76-week trial in adults with obesity or overweight. Topline results were disclosed on April 28, 2026: weight loss of up to 16.6% at 76 weeks (efficacy estimand), with absolute loss up to 17.8 kg (~39.2 lbs), versus 3.2% on placebo. This was the first Phase 3 obesity readout for survodutide.

SYNCHRONIZE-2 is a 76-week trial in 755 adults with obesity or overweight and type 2 diabetes. Results were presented at EASD and published in the New England Journal of Medicine on October 1, 2026: weight loss of up to 13.1% versus 3.1% on placebo (efficacy estimand), and HbA1c down by up to 1.21% from a baseline of 7.4%. Gastrointestinal side effects were the most common; 18% of people on survodutide stopped treatment because of them, versus 1.2% on placebo. A SYNCHRONIZE-1 MRI sub-study (n=75) presented the same day found muscle made up no more than 10% of the tissue lost.

Boehringer Ingelheim expects to present results from the cardiovascular outcomes trial, SYNCHRONIZE-CVOT, before the end of 2026, and has started a further Phase 3 trial in type 2 diabetes, SYNCHRONIZE-T2D (NCT07754461). It has not announced a filing timeline.

When Could Survodutide Be Approved?

No timeline has been confirmed. SYNCHRONIZE-1 read out on April 28, 2026 with weight loss of up to 16.6% at 76 weeks (efficacy estimand), and SYNCHRONIZE-2 followed on October 1, 2026 with up to 13.1% in type 2 diabetes. Boehringer Ingelheim has not announced an NDA or MAA filing window. Filing usually waits on the full pivotal dataset and safety database, including the SYNCHRONIZE-CVOT cardiovascular results that Boehringer expects to present before the end of 2026.

Several factors swing the calendar. Positive remaining Phase 3 data that hold the SYNCHRONIZE-1 efficacy signal would support filing; safety signals, requests for additional data, or manufacturing questions would extend it. See our survodutide vs retatrutide comparison for a side-by-side analysis of these two glucagon-engaging compounds.

Until Boehringer Ingelheim discloses its regulatory strategy, all approval-window numbers are speculation. Track every major milestone on our obesity drug approval tracker for 2026.

What About MASH?

Survodutide is also being evaluated for MASH (metabolic dysfunction-associated steatohepatitis, formerly called NASH) in two Phase 3 trials: LIVERAGE (MASH with F2–F3 fibrosis) and LIVERAGE-Cirrhosis (compensated MASH cirrhosis). The MASH path is a separate regulatory route from the obesity programme; both trials continue to recruit. No Phase 3 MASH readout has been published in 2026 to date.

The earlier Phase 2b MASH data were among the strongest reported for any investigational drug in this space, with approximately 64% of patients achieving MASH resolution at higher doses and material liver-fat reductions across dose groups. The glucagon-receptor arm of survodutide is thought to drive hepatic lipid oxidation, which lines up with the MASH biology.

If LIVERAGE / LIVERAGE-Cirrhosis eventually replicate those signals at Phase 3 scale, survodutide’s MASH path could become its primary regulatory differentiator versus pure GLP-1 and GLP-1/GIP agents. For a broader look at next-generation obesity agents, see our retatrutide vs tirzepatide vs CagriSema comparison.